Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon

Protein Engineering, Design and Selection

Volumn 23, Issue 4, 2010, Pages 271-278

  Walker, Adam ^a   Dunlevy, Gráinne ^a   Rycroft, Daniel ^a   Topley, Peter ^b   Holt, Lucy J ^a   Herbert, Tom ^a   Davies, Marie ^a   Cook, Fiona ^b   Holmes, Steve ^a   Jespers, Laurent ^a   Herring, Chris ^a  

^a Domantis Limited   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

AlbudAb; albumin; domain antibody; interferon; pharmacokinetics

Indexed keywords

AGONIST ACTIVITY; ALBUDAB; ALBUMIN; BINDING DOMAIN; DOMAIN ANTIBODY; HALF LIVES; HUMAN SERUM ALBUMINS; IN-VITRO; IN-VIVO; INTERLEUKIN-1; LIFE EXTENSION TECHNOLOGIES; LIFE EXTENSIONS; PLATFORM TECHNOLOGY; RECEPTOR ANTAGONISTS; SERUM ALBUMIN;

ANTIBIOTICS; BODY FLUIDS; GLYCOPROTEINS; PHARMACOKINETICS;

ANTIBODIES;

ALPHA2B INTERFERON; HUMAN SERUM ALBUMIN; SERUM ALBUMIN; SERUM ALBUMIN BINDING DOMAIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; EMBRYO; GENE FUSION; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; RAT; CHEMISTRY; GENETICS; IMMUNOLOGY; METHODOLOGY; PROTEIN ENGINEERING; SURFACE PLASMON RESONANCE; TUMOR CELL CULTURE;

ANTIBODIES; HUMANS; INTERFERON ALFA-2B; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; SURFACE PLASMON RESONANCE; TUMOR CELLS, CULTURED;

EID: 77954636621     PISSN: 17410126     EISSN: 17410134     Source Type: Journal    
DOI: 10.1093/protein/gzp091     Document Type: Article

References (34)

1. Adolf, G., Kalsner, I., Ahorn, H., Maurer-Fogy, I. and Cantell, K. (1991) Biochem. J., 276, 511-518.
2. Alexopoulou, L., Czopik Holt, A., Medzhitov, R. and Flavell, R.A. (2001) Nature, 413, 732-738.
3. Antonini, M.G., et al. (2008) Infection, 36, 250-255.
4. Brandt, E.R., Linnane, A.W. and Devenish, R.J. (1994) Br. J. Haematol., 86, 717-725.
5. Chaudhury, C., Brooks, C.L., Carter, D.C., Robinson, J.M. and Anderson, C.L. (2006) Biochemistry, 45, 4983-4990.
6. De Weerd, N.A., Samarajiwa, S.A. and Hertzog, P.J. (2007) J. Biol. Chem., 282, 20053-20057.
7. Diebold, S.S., Kaisho, T., Hemmi, H., Akira, S. and Reise Sousa, C. (2004) Science, 303, 1529-1531.
8. Domanski, P., Fish, E., Nadeau, O.W., Witte, M., Platanias, L.C., Yan, H., Krolewskii, J., Pitha, P. and Colamonici, O.R. (1997) J. Biol. Chem., 272, 26388-26393.
9. Durocher, Y., Perret, S. and Kamen, A. (2002) Nucleic Acids Res., 30, E9.
10. Glue, P., Fang, J.W.S., Rouzier-Panis, R., Raffanel, C., Sabo, R., Gupta, S.K., Salfi, M. and Jacobs, S. and The Hepatitis C Intervention Therapy Group (2000) Clin. Pharmacol. Ther., 68, 556-567.
11. Holt, L.J., Basran, A., Jones, K., Chorlton, J., Jespers, L.S., Brewis, N.D. and Tomlinson, I.M. (2008) Protein Eng. Des. Sel., 21, 283-288.
12. Hovanessian, A.G. (1991) J. Interferon Res., 11, 199-205.
13. Hui, D.J., Bhasker, C.R., Merrick, W.C. and Sen, G.C. (2003) J. Biol. Chem., 278, 39477-39482.
14. Hwang, S.Y., Hertzog, P.J., Holland, K.A., Sumarsono, S.H., Tymms, M.J., Hamilton, J.A., Whitty, G., Bertoncello, I. and Kola, I. (1995) Proc. Natl Acad. Sci. USA, 92, 11284-11288.
15. Jespers, L., Schon, O., Famm, K. and Winter, G. (2004) Nat. Biotechnol., 22, 1161-1165.
16. Li, X., Leung, S., Kerr, I.M. and Stark, G.R. (1997) Mol. Cell. Biol., 17, 2048-2056.
17. Loignon, M., Perret, S., Kelly, J., Boulais, D., Cass, B., Bisson, L., Afkhamizarreh, F. and Durocher, F. (2008) BMC Biotechnol., 8, 1-16.
18. Luft, T., Pang, K.C., Thomas, E., Hertzog, P., Hart, D.N.J., Trapani, J. and Cebon, J. (1998) J. Immunol., 161, 1947-1953.
19. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M. and Albrecht, J.K. and The International Hepatitis Interventional Therapy Group (2001) Lancet, 358, 958-965.
20. Marcus, P.I. and Salb, J.M. (1966) Virology, 30, 502-516.
21. McCafferty, J., Griffiths, A.D., Winter, G. and Chiswell, D. (1990) Nature, 348, 552-554.
22. McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M., Cort, S. and Albrecht, J.K. and The Hepatitis Interventional Therapy Group (1998) New Engl. J. Med., 339, 1485-1492.
23. Myint, A.M., Schwarz, M.J., Steinbusch, H.W.M. and Leonard, B.E. (2009) Metab. Brain Dis., 24, 55-68.
24. Osborn, B.L., Olsen, H.S., Nardelli, B., Murray, J.X., Zhou, H., Garcia, A., Moody, G., Zaritskaya, L.S. and Sung, C. (2002) J. Pharmacol. Exp. Ther., 303, 540-548.
25. Peters, T.P. (1977) Clin. Chem., 23, 5-12.
26. Platanias, L.C. (2005) Nat. Rev. Immunol., 5, 375-386.
27. Poynard, T., et al.The International Hepatitis Interventional Therapy Group (1998) Lancet, 352, 1426-1432.
28. Swann, J.B., Hayakawa, Y., Zerafa, N., Sheehan, K.C.F., Scott, B., Schreiber, R.D., Hertzog, P. and Smyth, M.J. (2007) J. Immunol., 178, 7540-7549.
29. Syed, S., Schuyler, P.D., Kulczycky, M. and Sheffield, W.P. (1997) Blood, 89, 3243-3252.
30. Ward, E.S., Gussow, D., Griffiths, A.D., Jones, P.T. and Winter, G. (1989) Nature, 341, 544-546.
31. Winter, G., Griffiths, A.D., Hawkins, R.E. and Hoogenboom, H.R. (1994) Annu. Rev. Immunol., 12, 433-455.
32. Yeh, P., et al. (1992) Proc. Natl Acad. Sci. USA, 89, 1904-1908.
33. Zeuzem, S., et al. (2008) Hepatology, 48, 407-417.
34. Zhao, H.L., Xue, C., Wang, Y., Li, X.Y., Xiong, X.H., Yao, X.Q. and Liu, Z.M. (2007) J. Biotechnol., 131, 245-252.